Endpoints News
Taiho, Cullinan report lung trial outcome Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Thu F
13 August, 2026
Announcing our $100M Series B
Aureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug Discovery
sponsored by Aureka Biotechnologies
presented by Ocular Therapeutix
The de­bate of dura­bil­i­ty in nAMD
top stories
1. Karyopharm has a month left to salvage its cancer expansion plans
2. Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
3.
news briefing
Zealand's royalty deal; Khartis raises money for TED drug
4. PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction
5. Four questions on new safety warnings for Neurocrine’s Vykat XR
6. Vaccine makers throw cold water on Trump’s push to split MMR vaccines
more stories
• 
Karen Weintraub
.

Commercial-stage cancer drugmaker Karyopharm Therapeutics is slated to run out of money next month if it doesn’t get a new infusion of cash, Kyle LaHucik reports. The company’s stock sank last month after a Phase 3 failure.
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Kyle LaHucik

A com­mer­cial-stage can­cer drug­mak­er with a mar­ket cap about one-third the size of its pro­ject­ed 2026 rev­enues is on the brink of de­fault­ing.

Karyopharm Ther­a­peu­tics...

Read the full story
2
by Ayisha Sharma

Tai­ho On­col­o­gy and Cul­li­nan Ther­a­peu­tics said Wednes­day that their next-gen EGFR in­hibitor has cleared a reg­is­tra­tional tri­al in the front-line set­ting of a ge­net­i­cal­ly-de­fined type...

Read the full story
Endpoints webinars
Aug 19
1:00 pm ET
From pilots to production: AI across R&D, safety, regulatory, and clinical
IBM
Aug 27
12:00 pm ET
Same molecule, different paths: Where value goes in cross-border dealmaking in a new era
PharmCube
Sep 03
11:00 am ET
How leading pharma organizations are putting AI agents to work
Medable
News Briefing: Quick hits from the biopharma web
3
by Kyle LaHucik

💸 Khar­tis Ther­a­peu­tics’ $50M Se­ries B: Forge Life Sci­ence Part­ners, Long­wood Fund, Lil­ly Asia Ven­tures and oth­er in­vestors backed the San Diego biotech’s lat­est round...

Read the full story
Endpoints 11 - Reserve Your Spot - Save $100 with our Early Bird rate
One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.
4